SCD-HeFT Results Justify Expanded ICD Coverage – Medtronic’s Stanton
This article was originally published in The Gray Sheet
Executive Summary
A CMS policy restricting ICD national coverage to a subgroup of the SCD-HeFT trial would undermine future clinical trial investment, according to Medtronic's Marshall Stanton, MD
You may also be interested in...
Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD
Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD
Guidant Launches Next Phase Of Heart Failure Registry To Promote ICDs
Guidant is turning from randomized trials to national patient registries to identify underserved heart failure patient groups that can benefit from implantable cardioverter defibrillators